Emphasis on Application (Neurological Disorders, Musculoskeletal Disorders, Ophthalmologic Disorders, and Others); End-User (Hospital, Clinics, and Others); Region/Country.
The Adeno-Associated Virus Gene Therapy Market was valued at approximately ~USD 2000 Million in 2023 and is expected to grow at a strong CAGR of around 39% during the forecast period (2024-2032) owing to the rising demand for targeted therapy.
The discovery and comprehension of novel gene delivery vectors have contributed to the recent upsurge in gene therapy initiatives. Adeno-associated virus (AAV) is a non-enveloped virus that has garnered a lot of interest in the industry, particularly in clinical-stage experimental therapy techniques. AAV can be modified to carry DNA to target cells. One of the safest methods for gene therapies to date has been the capacity to produce recombinant AAV particles with DNA sequences of interest for various therapeutic applications but without any viral genes.
This section discusses the key market trends that are influencing the various segments of the adeno-associated virus gene therapy market, as identified by our team of research experts.
Neurological Disorders Segment Transforming Industry
Neurological disorders are gaining significant attention in the AAV (Adeno-Associated Virus) gene therapy market due to several compelling factors. Firstly, the burden of neurological disorders, such as Alzheimer’s, Parkinson’s, and various genetic conditions, is rising globally, driving the demand for innovative treatments. Traditional therapies often fall short in effectively managing these complex conditions, creating a pressing need for advanced solutions. AAV gene therapy offers a promising approach by delivering precise genetic modifications directly to the affected cells, potentially addressing the root causes of these disorders. Additionally, advancements in AAV technology have improved its safety and efficacy profiles, making it a more viable option for targeting the central nervous system. Regulatory agencies’ growing support for gene therapy trials and the increasing investment in neuroscience research further bolster the development of AAV-based therapies for neurological disorders. These factors collectively contribute to the heightened interest and rapid growth of AAV gene therapy in the field of neurology.
Within North America, the U.S. holds a major share of the market. The region’s presence of pharmaceutical companies, supportive government programs, and surge in research and development investment are driving the market growth in the forthcoming years. For example, April 2024, U.S. FDA approved Pfizer’s BEQVEZ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B. Moreover, the rise in the prevalence of neurological and musculoskeletal disorders is also boosting the demand for AAV gene therapy in the region. According to the Parkinson Foundation, in 2022, nearly 90,000 people are diagnosed with Parkinson’s disease in the U.S. each year. This represents a steep 50% increase from the previously estimated rate of 60,000 diagnoses annually.
The adeno-associated virus gene therapy market is competitive, with several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new type launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Spark Therapeutics, Inc.; Novartis AG; Pfizer Inc.; UniQure N.V.; bluebird bio, Inc.; AveXis, Inc.; Ultragenyx Pharmaceutical Inc.; Freeline Therapeutics Holdings plc; LogicBio Therapeutics, Inc.; and MeiraGTx Holdings plc.
In January 2024, Charles River Laboratories launched off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.
In June 2023,S. FDA granted approval to Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.
The global adeno-associated virus gene therapy market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Executive Summary
4. Market Dynamics
5. Pricing Analysis
6. Global Adeno-associated Virus Gene Therapy Market Revenue (usd Mn), 2022-2032f
7. Market Insights By Application
8. Market Insights By End User
9. Market Insights By Region
10. Value Chain Analysis
11. Competitive Landscape
12. Company Profiled
13. Acronyms & Assumption
14. Annexure
Analyzing the historical market, estimating the current market, and forecasting the future market of the global adeno-associated virus gene therapy market were the three major steps undertaken to create and analyze the adoption of adeno-associated virus gene therapy in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global adeno-associated virus gene therapy market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the adeno-associated virus gene therapy market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the adeno-associated virus gene therapy market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as application, end-user and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the adeno-associated virus gene therapy market. Further, we conducted factor analysis using dependent and independent variables such as application, end-user and regions of the adeno-associated virus gene therapy market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and type launches in the adeno-associated virus gene therapy market sector across the globe.
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global adeno-associated virus gene therapy market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 22032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global adeno-associated virus gene therapy market. Data was split into several segments and sub-segments after studying various parameters and trends in the areas of the application, end-user and regions in the global adeno-associated virus gene therapy market.
The current & future market trends of the global adeno-associated virus gene therapy market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Q1: What is the adeno-associated virus gene therapy market's current market size and growth potential?
Q2: What are the driving factors for the growth of the adeno-associated virus gene therapy market?
Q3: Which segment has the largest share of the adeno-associated virus gene therapy market by end-user?
Q4: What are the emerging technologies and trends in the adeno-associated virus gene therapy market?
Q5: Which region will dominate the adeno-associated virus gene therapy market?
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
